Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.03B | 1.03B | 1.05B | 1.08B | 1.11B | 1.08B |
Gross Profit | 481.80M | 504.00M | 510.70M | 557.50M | 592.70M | 540.70M |
EBITDA | -62.80M | -83.60M | -16.50M | 22.50M | 185.20M | 145.40M |
Net Income | -138.60M | -156.20M | -80.50M | -40.40M | 111.10M | 75.00M |
Balance Sheet | ||||||
Total Assets | 1.24B | 1.23B | 1.43B | 1.65B | 1.72B | 1.62B |
Cash, Cash Equivalents and Short-Term Investments | 39.50M | 28.40M | 27.40M | 22.90M | 5.40M | 38.50M |
Total Debt | 100.00K | 569.50M | 610.10M | 625.20M | 56.90M | 50.50M |
Total Liabilities | 662.60M | 672.10M | 731.90M | 767.30M | 236.70M | 227.00M |
Stockholders Equity | 543.20M | 523.50M | 669.70M | 844.60M | 1.47B | 1.38B |
Cash Flow | ||||||
Free Cash Flow | 49.50M | 47.40M | 44.90M | 73.00M | 117.70M | 21.30M |
Operating Cash Flow | 51.80M | 51.20M | 48.40M | 80.10M | 123.30M | 24.90M |
Investing Cash Flow | 19.50M | -2.40M | -5.30M | -42.30M | -119.20M | -3.00M |
Financing Cash Flow | -69.90M | -48.30M | -40.50M | -18.60M | -36.10M | -16.70M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $8.82B | 28.81 | 17.66% | 0.16% | 16.80% | 39.99% | |
76 Outperform | $91.25B | 16.85 | -230.22% | 0.76% | 7.30% | 11.60% | |
71 Outperform | $3.22B | 36.28 | 7.85% | ― | 5.34% | ― | |
69 Neutral | $1.03B | 38.88 | 11.28% | ― | 30.04% | 43.47% | |
53 Neutral | $515.75M | ― | -12.03% | ― | 12.19% | -1.59% | |
52 Neutral | $475.99M | ― | -22.81% | ― | -1.08% | -65.84% | |
51 Neutral | $7.41B | 0.36 | -61.88% | 2.34% | 16.99% | 1.69% |
On June 26, 2025, Enhabit, Inc. held its Annual Meeting of Stockholders, where the 2025 Equity and Incentive Compensation Plan was approved. This plan, administered by the Compensation & Human Capital Committee, allows for various equity and cash-based awards to company officers, employees, and non-employee directors, with a total of 3,300,000 shares available for awards under specific conditions. Additionally, the meeting included the election of directors, ratification of PricewaterhouseCoopers LLP as the independent accounting firm, and an advisory vote on executive compensation.
The most recent analyst rating on (EHAB) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Enhabit, Inc stock, see the EHAB Stock Forecast page.
Enhabit, Inc. announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, where its executives will discuss the company’s strategic priorities and financial performance. The company has shown significant growth in its home health and hospice segments, with improvements in patient census and financial metrics, indicating a positive trajectory and reduced leverage, which may enhance its market position and stakeholder confidence.
The most recent analyst rating on (EHAB) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Enhabit, Inc stock, see the EHAB Stock Forecast page.
Enhabit, Inc. reported its first quarter 2025 financial results, highlighting a 3.7% sequential growth in home health census and a 12.3% year-over-year increase in hospice census. The company achieved a net income of $17.8 million and an adjusted EBITDA of $26.6 million, benefiting from improved profitability and a reduced leverage ratio, which allows for more favorable debt pricing and operational flexibility.